Skip to content
Sunday 16 August 2026London --:--Frankfurt --:--Zurich --:--
NewslettersSearchEN · DE
MorningWire

European business, markets and politics

FTSE 100
10,750.11
-0.21%
DAX
26,440.31
+0.53%
CAC 40
8,636.80
-0.16%
STOXX 50
6,539.59
-0.09%
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
More
GermanyFranceBankingAIEnergyFintechPropertyCapital Markets
  • Germany
  • France
  • Europe
  • Markets
  • Business
  • Economy
  • Technology
  • Politics
  • Opinion
  • DE
Wednesday 23 June 2021 4:37 pm  |  Updated:  Wednesday 23 June 2021 6:32 pm

Three in five adults in the UK have now received two vaccine doses

By: Amy O'Brien

Add as a preferred source on Google
Pop-up Vaccine Centre Opens In Newcastle
The EU Digital Covid Certificate only accepts vaccines currently approved by the EMA, which are: Pfizer-BioNTech, Moderna, Johnson & Johnson, and the Oxford-AstraZeneca vaccine made in Europe. (Photo by Ian Forsyth/Getty Images)

More than 60 per cent of adults in the UK have now received two doses of the Covid vaccine, as the rollout continues with pace.

The milestone follows last week’s extension of the vaccine invite to all over-18s in the UK.

75m doses of the Covid vaccines have now been administered in the UK, the Department of Health and Social Care said in its latest update.

43m first doses of the vaccine have been administered across the country – 83 per cent of the adult population. Over 31m people have now secured “the fullest possible protection” through a second jab, the DHSC said.

The UK reported 16,135 new Covid cases on Wednesday – the highest number of daily infections since the beginning of February.

Coronavirus-related deaths remained low, however, with 19 deaths reported in the latest 24-hour period.

Reports emerged earlier today that 41 cases of a mutation of the Delta variant of coronavirus, being labelled “Delta plus”, have been found in England.

Read more

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

Asked if the government knows if the vaccines are effective against the mutation, the Prime Minister’s official spokesperson said: “Not at this stage. We have not got trial results of that.

“It’s something that we are monitoring carefully and there is work going on both here and internationally on this.

Speaking at the Downing Street press conference, vaccines minister Nadhim Zahawi said that the vaccine programme has already saved 14,000 lives. “I can share that now it has prevented over 44,500 hospitalisations in England alone,” he said. “That’s 2,500 hospitalisations prevented in the past two weeks.”

Zahawi said that a “concerted community effort” had reduced vaccine hesitancy throughout the country, particularly among ethnic minorities.

The government and health officials will now “hone in” on areas where the vaccine take up has been lower, Zahawi said.

The minister announced that a dedicated London summit will take place on Friday, aiming to scrutinise why the take-up of first vaccine doses in London “is slightly behind compared to others in the UK”.

PHE analysis published last week showed that both the Pfizer and AstraZeneca vaccines are over 90 per cent effective at preventing hospitalisations from the Delta variant after two doses, and 75 per cent effective after one dose.

Read more

Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

Share this article

  • Facebook
  • X
  • LinkedIn
  • WhatsApp
  • Email

Similarly tagged content:

Sections

  • News

Categories

  • Business

Related Topics

  • Coronavirus
  • Vaccine

Trending Articles

  • Grandparents fund university degrees to avoid inheritance tax net

  • Revolut chatbot goes rogue by charging users to cancel subscription

  • Brompton Bicycle sues former adviser for ‘professional negligence’

  • Revolut takes flight with launch of new airport lounges

  • Is the Zeekr 9X Super Hybrid the new luxury SUV to beat?

More from Morning Wire

  • Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

    Business Wire
  • Cycle Pharmaceuticals Selects Forma Life Sciences to Establish U.S. Commercial Supply for FDA-Approved CAVHANZA™ (nilotinib) Orally Disintegrating Tablets

    Business Wire
  • ILiAD Biotechnologies Expands Board of Directors and Appoints Chief Business Officer

    Business Wire
  • Dompé Doses First Patient in Phase 3 Study of Cenegermin-bkbj in NAION

    Business Wire
  • LegadoSign Selected by Aberdeen Adviser to Power Secure Digital Onboarding at Scale

    Business Wire
  • Silence Therapeutics Announces Positive Topline Results from Phase 2 SANRECO Trial of Divesiran in Polycythemia Vera, Supporting its Potential Best-in-Class Profile

    Business Wire
  • ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults; alongside INSTI-powered long-acting injectable innovation at AIDS 2026

    Business Wire
  • Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026

    Business Wire
MorningWire

Independent European business, markets and political news for decision-makers.

Morning Briefing

Europe

  • Germany
  • France
  • Europe
  • UK & Ireland

Business

  • Markets
  • Banking
  • Technology
  • Energy
  • Property
  • Fintech

Editorial

  • Opinion
  • Editorial Policy
  • Corrections
  • Contact

Company

  • About Morning Wire
  • Privacy Policy
  • Terms of Use
  • Cookie Policy
© 2026 Morning Wire Ltd · Published by Morning Wire Media, Bahnhofstrasse 65, 8001 Zürich, Switzerland
Privacy · Terms · Cookies · Facebook